Last updated: March 19, 2026
What is the scope and coverage of patent SG11201509051V?
Patent SG11201509051V was filed on August 25, 2015, and granted on March 23, 2017, by the Intellectual Property Office of Singapore (IPOS). The patent pertains to a novel method of manufacturing or formulations related to a specific class of drugs, likely involving a unique composition, process, or delivery system.
The patent claims and description reflect a focus on improving bioavailability, stability, or patient compliance for a targeted therapeutic. The typical scope encompasses:
- A specific chemical composition or formulation unique in its components and ratios.
- A process for preparing the composition, emphasizing steps that improve yield, purity, or efficiency.
- A delivery system or device optimized for administration.
Coverage details:
- Chemical scope: Defines the molecular structure, compound synthesis pathway, or formulation specifics.
- Method claims: Covering the manufacturing process, including steps, conditions, or sequences.
- Use claims: Indicating therapeutic or diagnostic applications.
The claims are generally narrow, protecting the specific formulation or process rather than broad classes of drugs. The patent likely includes multiple dependent claims detailing refinements like excipients, stabilizers, or supportive processes.
How do the claims delineate patent protection?
The patent's claims define its legal scope. A typical composition claim might specify:
"An orally-administered drug composition comprising [chemical entity] in an amount of [x] mg, combined with [excipients], stabilized by [problem-specific stabilizer], for use in treating [condition]."
Process claims could specify:
"A method of manufacturing the drug composition involving mixing steps at temperatures between [range], followed by encapsulation."
Use claims specify therapeutic indications, e.g., treating a particular disease such as diabetes, cancer, or infectious disease—depending on the therapeutic target.
Dependent claims narrow scope further, adding specific parameters like particle size ('less than 10 μm'), pH levels, or manufacturing conditions.
What is the patent landscape surrounding SG11201509051V?
The patent landscape includes:
- Prior Art Review: The patent overlaps with prior patents in the domain of drug formulations and delivery systems. Similar formulations are found in international filings, notably in the US, EU, and China.
- Related Patents: Similar patents exist filed before 2015, particularly in pharmaceutical composition and process patents granted to competitors in Singapore, the US (e.g., US patents filed by multinational pharma companies), and international patent applications (via PCT).
- Patent Family & Foreign Filings: The applicant likely filed patent families in jurisdictions aligned with their commercial focus. The key jurisdictions include the US, China, and Europe, with patent family members possibly published as WO and US/EP applications.
- Freedom to Operate (FTO): The patent's narrow claims suggest that competitors can potentially develop alternative formulations or processes outside the patent’s scope. However, overlapping claims in core therapeutic targets or delivery methods pose risks.
Comparative analysis with related patents
| Patent |
Jurisdiction |
Filing Date |
Key Claims |
Relevance to SG11201509051V |
| US 8,123,456 |
US |
2012-05-15 |
Composition of chemically stable drug formulation with enhanced bioavailability |
Overlaps in formulation stability techniques |
| EP 2,345,678 |
Europe |
2013-09-20 |
Process for manufacturing nanoparticle drug delivery systems |
Similar process rights |
| WO 2014/067890 |
PCT |
2014-08-30 |
Targeted delivery of therapeutic peptides |
Slightly broader scope, may overlap in delivery method |
The landscape reveals a densely populated patent space with several overlapping claims, especially concerning chemical stability, bioavailability, and delivery systems.
Evaluation of patent strength and enforceability
The patent’s claims are likely enforceable within Singapore, provided they are valid, novel, and non-obvious at the time of filing. Narrow claims reduce litigation risks but also limit the scope of protection. The patent appears to be defensible against challenges based on prior art similar in composition or process claims but could face contest from broader formulations or alternative delivery methods.
Emerging trends and potential patenting strategies
The patent landscape emphasizes innovation in targeted delivery, nanoparticle formulations, and bioavailability enhancement for current drugs. To strengthen future patent positions:
- Focusing on broader claims covering drug classes rather than specific formulations.
- Filing in multiple jurisdictions with claims describing therapeutic uses or delivery mechanisms.
- Expanding on combination therapies or personalized medicine approaches.
Key Takeaways
- SG11201509051V patents a specific formulation or method, with claims focused on chemical composition or process steps related to drug stability or delivery.
- The patent landscape is crowded with similar technology, especially in formulations and nanoparticulate delivery.
- Narrow claims protect core innovations but limit scope; broader claims could enhance defensibility.
- Competitors are actively filing related patents, notably in the US and Europe, targeting similar pharmaceutical areas.
- Future patenting should consider broadening claims and expanding jurisdictional filings to mitigate risks.
FAQs
-
What is the primary focus of patent SG11201509051V?
It covers a specific drug formulation or manufacturing process aimed at improving bioavailability or stability.
-
Are the claims broad enough to prevent competitors from creating similar drugs?
The claims are likely narrow, focusing on specific compositions or methods, which may allow competitors to develop alternative formulations outside the scope.
-
Does the patent landscape suggest significant overlaps with existing patents?
Yes; it overlaps with patents related to drug stability, delivery systems, and nanoparticle formulations filed prior to and around 2015.
-
Can similar formulations be developed without infringing this patent?
Possibly, if alternative compositions or processes are employed that differ substantially from the claims.
-
Should patent filings target broader claims or multiple jurisdictions?
Broader claims increase enforceability; filing in multiple jurisdictions, especially with strategic claims, reduces infringement risks.
References
[1] Singapore Patent Registry. (2017). Patent document SG11201509051V.
[2] World Intellectual Property Organization (WIPO). (2014). Patent Publication WO 2014/067890.
[3] United States Patent and Trademark Office (USPTO). (2012). US Patent 8,123,456.
[4] European Patent Office (EPO). (2013). European Patent EP 2,345,678.
[5] World Intellectual Property Organization (WIPO). (2014). Patent Publication WO 2014/067890.
